Evogene shares rise 10.90% intraday after appointing Dr. Olga Nissan as VP of Business Development.

Evogene surged 10.90% intraday following the announcement of Dr. Olga Nissan’s appointment as Vice President of Business Development, effective January 1, 2026. Dr. Nissan, a biotechnology and pharmaceutical executive with 15+ years of experience in R&D, clinical development, and business operations, is expected to strengthen Evogene’s AI-driven drug discovery capabilities and strategic partnerships. Her track record at firms like Protica Bio, EcoPhage, and Teva, along with her academic expertise in biochemistry, positions her to accelerate the company’s expansion in small-molecule therapeutics. CEO Ofer Haviv highlighted her role in scaling ChemPass AI-powered discovery and expanding industry collaborations, aligning with the stock’s sharp intraday rally as investors likely interpreted the hire as a catalyst for growth and innovation.